share_log

Needham Maintains Buy on Harmony Biosciences, Lowers Price Target to $50

Benzinga ·  Feb 23 05:44

Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and lowers the price target from $53 to $50.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment